Richeng Jiang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0002-3757-2219

发表论文 72 篇 · 总被引 2451 次 · h-index 21

代表论文

• PIM1/NF-κB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC (2024 · Oncogene · 被引 22)
• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer (2024 · Thoracic Cancer · 被引 19)
• PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer (2024 · Cell Death and Disease · 被引 18)
• Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study (2023 · Molecular Cancer · 被引 17)
• Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer (2024 · Gynecologic Oncology · 被引 11)
• Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients (2024 · BMC Cancer · 被引 8)